| Bioactivity | S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS)[1]. |
| Invitro | S1P1 agonist 5 (compound 21l) shows excellent in vitro efficacies with EC50s of 7.03 nM and 11.8 nM for β-arrestin recruitment and internalization, respectively[1]. |
| In Vivo | S1P1 agonist 5 shows good oral bioavaliabily in rats (F=54.2%) and dogs (F=31.8%)[1].S1P1 agonist 5 (10 mg/kg; p.o.) inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood and that lymphopenia can be recovered within 24 hours[1].S1P1 agonist 5 (3, 10 mg/kg, p.o., once daily for 20 days) ameliorates the disease progression and overall severity in EAE mice, showing favorable drug-like properties[1].Pharmacokinetic Parameters of S1P1 in rats, male beagle dogs[1]. administration |
| Name | S1P1 agonist 5 |
| Formula | C23H24ClN2NaO4 |
| Molar Mass | 450.89 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Park SJ, et al. Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. J Med Chem. 2022; 65(4):3539-3562. |